Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Keytruda resistance shown as a monotherapy in anal cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 05, 2024 9:14pm

100 Views

Post# 35864421

RE:RE:RE:Keytruda resistance shown as a monotherapy in anal cancer

Why?? ...those manipulative trader/brokers like you numbersxnumbers, and the likes of Quentin30, lonc17, O'henry,, Lesalpes29, Venture009, CMHarring218431, and crew on this and other message boards, through the apparent likes of CIBC World Markets and Canacccord, as examples, have been involved in manipulating the price of this stock at a "full bore" pace, unsuccesffuly trying to acquire a controlling interest in the stock and would like you to think differently.

<< Previous

Bullboard Posts

Next >>

Quebecor achieves all Freedom Mobile acquisition commitments